ALXO - ALX Oncology Holdings Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Burlingame,
United States
Type: Equity
ALXO price evolution
ALXO
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $15.53 | $14.04 | $22.41 | |
| Short term investments | $141.19 | $143.4 | $160.33 | |
| Net receivables | $1.15 | $1.2 | $1.1 | $1 |
| Inventory | ||||
| Total current assets | $155.9 | $168.71 | $167.86 | $188.66 |
| Long term investments | $29.48 | $27.05 | $35.41 | |
| Property, plant & equipment | $10.31 | $3.32 | $3.44 | $3.59 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $45.91 | $44.79 | $53.89 | |
| Total investments | $170.66 | $170.44 | $195.74 | |
| Total assets | $185.72 | $214.62 | $212.65 | $242.55 |
| Current liabilities | ||||
| Accounts payable | $7.89 | $8.37 | $6.6 | $9.13 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $32.34 | $38.45 | $32.23 | $36 |
| Long term debt | $11.78 | $9.77 | $9.7 | $9.64 |
| Total noncurrent liabilities | $16.85 | $16.23 | $16.84 | |
| Total debt | $9.77 | $9.7 | $9.64 | |
| Total liabilities | $48.91 | $55.3 | $48.45 | $52.84 |
| Shareholders' equity | ||||
| Retained earnings | -$591.96 | -$561.25 | -$521.85 | -$486.27 |
| Other shareholder equity | $0.56 | -$0.07 | $0.03 | $0.26 |
| Total shareholder equity | $159.32 | $164.19 | $189.71 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $22.41 | $48.82 | $363.67 | $434.22 |
| Short term investments | $160.33 | $217.38 | ||
| Net receivables | $1 | |||
| Inventory | ||||
| Total current assets | $188.66 | $270.97 | $367.02 | $435.99 |
| Long term investments | $35.41 | $16.7 | ||
| Property, plant & equipment | $3.59 | $9.79 | $0.9 | $0.05 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $53.89 | $35.52 | $13.16 | $0.06 |
| Total investments | $195.74 | $234.08 | ||
| Total assets | $242.55 | $306.49 | $380.18 | $436.05 |
| Current liabilities | ||||
| Accounts payable | $9.13 | $8.07 | $5.39 | $0 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $36 | $28.32 | $15.29 | $6.2 |
| Long term debt | $9.64 | $9.39 | $0.28 | |
| Total noncurrent liabilities | $16.84 | $14.7 | $1.84 | $0.01 |
| Total debt | $9.64 | $9.39 | ||
| Total liabilities | $52.84 | $43.02 | $17.13 | $6.21 |
| Shareholders' equity | ||||
| Retained earnings | -$486.27 | -$325.47 | -$201.99 | -$118.52 |
| Other shareholder equity | $0.26 | -$0.84 | ||
| Total shareholder equity | $189.71 | $263.46 | $363.05 | $429.85 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $34.65 | $31.72 | $41.78 | |
| Selling, general & administrative | $6.87 | $6.04 | $6.24 | |
| Total operating expenses | $41.52 | $37.76 | $48.02 | |
| Operating income | -$41.52 | -$37.76 | -$48.02 | |
| Income from continuing operations | ||||
| EBIT | -$38.97 | -$35.15 | -$45.06 | |
| Income tax expense | ||||
| Interest expense | $0.43 | $0.43 | $0.41 | |
| Net income | ||||
| Net income | -$39.4 | -$35.58 | -$45.47 | |
| Income (for common shares) | -$39.4 | -$35.58 | -$45.47 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1.18 | |||
| Cost of revenue | $1.07 | |||
| Gross Profit | -$1.07 | |||
| Operating activities | ||||
| Research & development | $141.79 | $98.4 | $60.17 | $28.96 |
| Selling, general & administrative | $28.48 | $29.04 | $23.39 | $14.81 |
| Total operating expenses | $170.28 | $127.44 | $83.56 | $43.77 |
| Operating income | -$170.28 | -$127.44 | -$83.56 | -$44.84 |
| Income from continuing operations | ||||
| EBIT | -$159.24 | -$123.42 | -$83.47 | -$44.69 |
| Income tax expense | $0.06 | -$0.02 | $0.24 | |
| Interest expense | $1.56 | $0.01 | $0.81 | |
| Net income | ||||
| Net income | -$160.81 | -$123.48 | -$83.46 | -$45.74 |
| Income (for common shares) | -$160.81 | -$123.48 | -$83.46 | -$50.94 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$39.4 | -$35.58 | -$45.47 | |
| Operating activities | ||||
| Depreciation | $0.22 | $0.21 | $0.21 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $7.25 | $7.03 | $6.72 | |
| Total cash flows from operations | -$26.57 | -$37.92 | -$39.68 | |
| Investing activities | ||||
| Capital expenditures | -$0.09 | -$0.15 | -$0.15 | |
| Investments | $1 | $26.62 | -$16.52 | |
| Total cash flows from investing | $53.07 | $0.91 | $26.47 | -$16.67 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $27.37 | $3.26 | $59.23 | |
| Net borrowings | -$0.22 | -$0.17 | -$0.06 | |
| Total cash flows from financing | $30.49 | $27.15 | $3.09 | $59.17 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$6.3 | $1.49 | -$8.37 | $2.82 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$160.81 | -$123.48 | -$83.46 | -$45.74 |
| Operating activities | ||||
| Depreciation | $0.84 | $0.34 | $0.05 | $0.2 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $26.27 | $23.84 | $13.91 | $5.44 |
| Total cash flows from operations | -$130.36 | -$89.22 | -$68.1 | -$38.29 |
| Investing activities | ||||
| Capital expenditures | -$1.27 | -$1.43 | -$0.67 | -$0.03 |
| Investments | $45.93 | -$233.99 | ||
| Total cash flows from investing | $44.66 | -$235.42 | -$0.67 | $0.61 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $59.68 | $0.9 | $2.75 | $368.56 |
| Net borrowings | -$0.39 | $8.96 | -$0.28 | -$6.51 |
| Total cash flows from financing | $59.29 | $9.86 | $2.47 | $462.88 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$26.42 | -$314.78 | -$70.55 | $425.2 |
News
Fundamentals
| Market cap | $85.44M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 52.74M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.28 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 4.82 |
| Quick ratio | N/A |